文献速递泌尿生殖MR

多参数MRI能否在外照射放疗前替代Roach方程进行前列腺癌分期

Can multiparametric MRI replace Roach equations in staging prostate cancer before external beam radiation therapy?
PubMed 文献 · Eur J Radiol · 2016-10-22

本研究对73例经活检证实的前列腺癌患者在前列腺外照射放疗前行3.0T多参数MRI,比较Roach方程与mpMRI在T分期和风险分组上的一致性;另在37例根治性前列腺切除术后组织学检查组中验证mpMRI对≥T3期的敏感度和特异度。结果显示两者一致性中等,mpMRI使约五分之一患者风险分组发生改变,且验证组中mpMRI对≥T3期具有较高敏感度和特异度。

要点

  • Roach方程与mpMRI评估前列腺癌T分期的一致性为中等(k=0.53)。
  • mpMRI使21.9%患者T分期、20.5%患者风险分组发生改变,多以下调为主。
  • 验证组中mpMRI诊断≥T3期的敏感度81.8%、特异度88.5%。

核心结论

  • Roach方程与mpMRI在前列腺癌T分期评估中仅呈中等一致性,导致约五分之一患者风险评估因mpMRI而改变;验证组中mpMRI对≥T3期的高敏感度和特异度支持其作为外照射放疗前前列腺癌分期工具。

研究设计与样本

  • 前瞻性研究,73例经活检证实的前列腺癌患者在外照射放疗前行3.0T多参数MRI,并与既往Roach方程评估比较;另设37例根治性前列腺切除术后组织学检查作为mpMRI验证组。

诊断标准与关键数值

  • 以Cohen kappa统计量评估Roach方程与mpMRI在T分期(≥T3 vs T≤2)和NCCN风险分组(≤中危 vs ≥高危)上的一致性,k值分别为0.53和0.56;验证组中mpMRI诊断≥T3期的敏感度为81.8%(95%CI 65.1-91.9),特异度为88.5%(95%CI 72.8-96.1)。

临床应用与阅片要点

  • mpMRI可使约21.9%患者T分期和20.5%患者风险分组发生改变,且多以下调前列腺癌分期为主;验证组中mpMRI对≥T3期具有较高敏感度和特异度,支持其在外照射放疗前用于前列腺癌分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the agreement between Roach equations (RE) and multiparametric magnetic resonance imaging (mpMRI) in assessing the T-stage of prostate cancer (PCa).

MATERIALS AND METHODS: Seventy-three patients with biopsy-proven PCa and previous RE assessment prospectively underwent mpMRI on a 3.0T magnet before external beam radiation therapy (EBRT). Using Cohen's kappa statistic, we assessed the agreement between RE and mpMRI in defining the T-stage (≥T3 vs.T≤2) and risk category according to the National comprehensive cancer network criteria (≤intermediate vs. ≥high). We also calculated sensitivity and specificity for ≥T3 stage in an additional group of thirty-seven patients with post-prostatectomy histological examination (mpMRI validation group).

RESULTS: The agreement between RE and mpMRI in assessing the T stage and risk category was moderate (k=0.53 and 0.56, respectively). mpMRI changed the T stage and risk category in 21.9% (95%C.I. 13.4-33-4) and 20.5% (95%C.I. 12.3-31.9), respectively, prevalently downstaging PCa compared to RE. Sensitivity and specificity for ≥T3 stage in the mpMRI validation group were 81.8% (95%C.I. 65.1-91.9) and 88.5% (72.8-96.1).

CONCLUSION: RE and mpMRI show moderate agreement only in assessing the T-stage of PCa, translating into an mpMRI-induced change in risk assessment in about one fifth of patients. As supported by high sensitivity/specificity for ≥T3 stage in the validation group, the discrepancy we found is in favour of mpMRI as a tool to stage PCa before ERBT.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Girometti R, Signor MA, Pancot M, et al. Can multiparametric MRI replace Roach equations in staging prostate cancer before external beam radiation therapy? Eur J Radiol. 2016. PMID: 27842672. doi:10.1016/j.ejrad.2016.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。